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Wegenerated novel recombinant influenza Aviruses (vNA38) harboring dicistronic NA segments with an extended native 5V terminal sequence of
70 nucleotides comprised of the last 42 nucleotides of the NAORF and the 5V noncoding region (5VNCR). vNA38 viruses replicated stably and more
efficiently than vNA35 viruses with a dicistronic NA segment comprised of the native 5V NCR only, that we described previously (Vieira Machado,
A., Naffakh, N., van der Werf, S., Escriou, N., 2003. Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic
genomic segment with an internal promoter. Virology 313, 235–249). In addition, vNA38 viruses drove the expression of higher levels of encoded
heterologous proteins than corresponding vNA35 viruses, both in cell culture and in the pulmonary tissue of infected mice. These data demonstrate
that a sequence overlapping 5V coding and noncoding regions of the NA segment determines efficient replication and/or propagation of the vRNA.
Intranasal immunization of mice with live vNA38 viruses induced B and Tcell responses specific for the heterologous protein expressed, establishing
the usefulness of such recombinant influenza viruses with a dicistronic segment for the development of live bivalent vaccines.
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Mengo virusIntroduction
The genome of influenza A viruses consists of eight
molecules of single-stranded RNA of negative polarity. The
viral RNAs (vRNAs) are associated with the nucleoprotein
(NP) and with the three subunits of the polymerase complex
(PB1, PB2 and PA) to form ribonucleoproteins (RNPs). Once
released in the infected cells, the RNPs are transported to the
nucleus, where they undergo transcription and replication (for a
review, see Lamb and Krug, 2001). The three subunits of the
polymerase and the NP are the minimum set of proteins
required for both processes, although the molecular mechan-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Antoˆnio Carlos 6627, Belo Horizonte, Minas Gerais, Brazil.isms involved are clearly different. The initiation of transcrip-
tion involves a cap-stealing mechanism, by which 5V-capped
oligonucleotides derived from cellular mRNA are used as
primers and elongated by the viral polymerase (Bouloy et al.,
1978; Krug et al., 1979; Plotch et al., 1981). Termination and
polyadenylation occur at a stretch of five to seven U residues
close to the 5V end of the template (Luo et al., 1991; Poon et al.,
1999; Pritlove et al., 1998). In the replication process, full-
length positive-stranded RNAs complementary to the vRNAs
(cRNAs) are produced, which serve as templates for amplifi-
cation of the vRNAs. Initiation of the synthesis of cRNAs and
vRNAs is primer-independent, and anti-termination occurs at
the poly-U sequence during the synthesis of the cRNA
(reviewed in Hay, 1998).
The signals necessary for transcription, replication and
packaging of the genome segments have been shown to be
located within the 5V and 3V noncoding regions (NCR) of the
genomic RNA segments of influenza Aviruses, including highly
conserved sequences of 13 nucleotides (nt) at the 5V end and 12
nt at the 3V end (Luytjes et al., 1989; Neumann et al., 1994). The06) 73 – 87
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to each other and interact to form a partially double-stranded
‘‘corkscrew’’ structure (Flick et al., 1996). They are both
required for initiation of transcription through interaction with
the PB1 subunit of the polymerase complex (Li et al., 1998;
Tiley et al., 1994) and constitute the 5V and 3V arm of the vRNA
promoter, respectively. In addition, nonconserved sequences of
the noncoding regions, 7 to 45 nt in length, were found to
modulate the efficiency of transcription/replication (Bergmann
and Muster, 1996; Zheng et al., 1996). Recently, packaging
signals of the NA, HA andNS segments were found to be located
not only within the NCRs but also in adjacent coding sequences
(Fujii et al., 2003, 2005; Watanabe et al., 2003).
The genome of influenza A viruses codes for 11 proteins.
Most genomic segments are monocistronic, except segment
PB1 which encodes an additional PB1-F2 protein through the
use of an alternate start codon (Chen et al., 2001), and
segments M and NS which encode proteins M2 and NEP in
addition to M1 and NS1, respectively, through an alternate
splicing mechanism (for a review, see Lamb and Krug, 2001).
Using reverse genetics techniques, several strategies have been
explored to generate recombinant influenza viruses expressing
additional heterologous proteins (reviewed in Garcia Sastre,
2000). Some of these strategies are based on the expression of a
chimeric viral protein. Recombinant influenza viruses contain-
ing an HAwith up to 12 aa inserted into the antigenic sites B or
E (Gonzalo et al., 1999; Li et al., 1993) or an NA with foreign
epitope insertions in the stalk (Castrucci et al., 1992; Efferson
et al., 2003; Muster et al., 1995) have been recovered. Other
strategies were designed in order to generate recombinant
viruses expressing foreign polypeptides as independent pro-
teins. Engineering of a ninth synthetic pseudoviral RNA,
containing a foreign ORF in negative polarity flanked by the 5V
and 3V NCRs of an influenza segment, resulted in the
replication and packaging of this RNA segment into influenza
virions (Lu et al., 2004; Luytjes et al., 1989; Neumann et al.,
1994). However, the ninth additional segment expressing a
nonessential foreign protein was usually lost upon serial
passages. Introduction of mutations in the 3V NCR that
conferred a replicative advantage over the other eight virus
segments allowed a ninth nonessential segment to be main-
tained in the viral progeny for more than 10 passages
(Neumann and Hobom, 1995; Zhou et al., 1998). Nevertheless,
the proportion of the foreign gene segment still could fluctuate
from generation to generation, resulting in variable levels of
expression of the corresponding polypeptide. Stable expression
of a foreign protein by influenza A viruses was achieved by
engineering viral genes encoding fusion proteins or dicistronic
genes. Large polypeptides such as the CAT or GFP proteins
were stably expressed by influenza A virus vectors as a fusion
protein containing an autocatalytic cleavage site or a caspase
cleavage site between the viral gene product (usually NA or
NS1) and the foreign polypeptide (Ferko et al., 2001; Kittel et
al., 2004; Percy et al., 1994). A drawback of this method is
that, due to the remaining of amino acids from the cleavage
site, the expression of the viral and/or the foreign protein is
altered. Stable expression of a foreign polypeptide byrecombinant influenza A viruses has also been achieved by
engineering a dicistronic NA segment containing an internal
ribosome entry site ‘‘IRES’’ (Garcia-Sastre et al., 1994).
Following transcription of a dicistronic mRNA, translation of
the foreign polypeptide and NA protein occurred via cap-
dependent and cap-independent (IRES-mediated) initiation of
translation, respectively.
Flick and Hobom introduced a new principle for making an
influenza segment dicistronic at the transcription/replication
level, by demonstrating that the influenza virus polymerase
complex was able to recognize an additional 3V promoter
sequence located between two reporter genes in a recombinant
vRNA-like molecule (Flick and Hobom, 1999). Based on their
observations, we explored in a previous study the possibility of
rescuing recombinant influenza A viruses which harbored a
dicistronic NA segment with a foreign gene under the control
of a duplicated 3V promoter sequence (Vieira Machado et al.,
2003). Such recombinant viruses (namely, vNA35 viruses)
were found to replicate stably both in vitro in cell culture and in
vivo in the pulmonary tissue of infected mice. In infected
MDCK cells, subgenomic vRNA and mRNAwere synthesized
under the control of the internal 3V promoter, which resulted in
low but significant expression of the foreign gene product (e.g.,
the CAT protein) in a native form. However, the vNA35
recombinant viruses harboring a dicistronic NA segment
showed a reduced growth capacity as compared to the wild-
type virus, which was correlated with a reduced expression of
the NA protein in infected cells.
In the present study, we tried to improve the characteristics
of the vNA35 dicistronic viruses as vectors for the expression
of heterologous genes. Based on the observation by Zheng et
al. that the noncoding extremities of each segment are specific
to the ORFs they contain (Zheng et al., 1996), we made the
hypothesis that some signals important for the replication and/
or propagation of the vRNAs could be disrupted in the vNA35
dicistronic segments, due to the separation of the 5V NCR from
the end of the NA coding sequence. Thus, we generated and
characterized a new generation of dicistronic viruses named
vNA38, similar to the vNA35 viruses except for the fact their
NA segments comprise an extended native 5V terminal
sequence of 70 nucleotides, as compared to 28 nucleotides
for the vNA35 viruses. This was achieved by duplicating the
last 42 nucleotides of the NA ORF upstream from the 5V NCR.
Meanwhile, Fujii et al. demonstrated that both ends of the NA
vRNA coding region were required for incorporation of the NA
segment into virions (Fujii et al., 2003), strongly suggesting a
role of the coding sequences in selective packaging of the
vRNAs, and thus providing an additional rationale for the
design of the vNA38 viruses. Indeed, we found that vNA38
viruses replicated more efficiently than vNA35 viruses, both in
cell culture and in the pulmonary tissue of infected mice. In
addition, vNA38 viruses drove the expression of higher levels
of encoded heterologous proteins than corresponding vNA35
viruses. We demonstrated that intranasal immunization of mice
with live recombinant vNA38 viruses was able to induce a B
and CD8+ T cell response specific for the expressed
heterologous genes.
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CAT expression from recombinant dicistronic NA vRNAs
conserving 28 nt (vNA35-CAT) or 70 nt (vNA38-CAT) from
the wild-type NA vRNA 5V terminal sequence
In an attempt to improve the design of dicistronic influenza A
viruses as vectors for the expression of an heterologous protein,
we modified the plasmids of the NA35 series described earlier
(Vieira Machado et al., 2003), from which dicistronic influenza
vRNA-like molecules can be transcribed by the RNA polymer-
ase I. Plasmid pPR-NA38 was obtained by inserting a
duplication of the last 42 nt of the NA ORF between the
multiple cloning site (MCS) and the 5V noncoding sequence of
the NA segment of WSN in plasmid pPR-NA35 (Fig. 1).
Subsequently, the three reporter genes that had previously been
inserted in the MCS of pPR-NA35 (Vieira Machado et al., 2003)
were inserted in the MCS of pPR-NA38: the CAT gene (660 nt),
the GFP gene of Aequorea victoria (720 nt) and a sequence
coding for a fragment of the VP0 capsid protein of Mengo virusFig. 1. Schematic representation of the plasmids used in reverse genetics
experiments for the synthesis of A/WSN/33 virus-derived dicistronic NA
segments. Plasmid pPR-NA35 was derived from plasmid pPR-NA, which
contains the full-length NA segment of A/WSN/33 virus in negative-sense
orientation under the control of a truncated human polI promoter, as described
earlier (Vieira Machado et al., 2003). It contains a recombinant NA segment
cDNA, in which the NA coding sequence is followed by a duplicated 3V
noncoding region (3V NCR), an XhoI-NheI multiple cloning site (MCS), and the
original 5V noncoding region (5V NCR). The pPR-NA37 plasmid was derived
from pPR-NA35 by deletion of the duplicated 3V NCR sequence. The pPR-
NA38 plasmid was derived from pPR-NA35 by insertion of a duplication of the
last 42 nt of the NA ORF (open box) at the NheI restriction site located between
the internal 3V NCR and the terminal 5V NCR sequences. The sequences
encoding VP0c, CAT and GFP polypeptides were inserted between the XhoI
and NheI restriction sites of pPR-NA35 or pPR-NA38, to generate plasmids
pPR-NA35-VP0c, -CAT and -GFP, or plasmids pPR-NA38-VP0c, -CAT and
-GFP, respectively. P-pol1: truncated human RNA polymerase I promoter (nt
254 to 1). HDV-R: hepatitis y virus genomic ribozyme.(VP0c, 306 nt). Thus, plasmids of both the pPR-NA35 and pPR-
NA38 series direct the synthesis of vRNA-like molecules which
contain the NAORF downstream of the original 3V promoter and
a second ORF (CAT, GFP or VP0c) downstream of the
duplicated 3V promoter. However, pPR-NA38 derived vRNAs
are identical to the wild-type (wt) NA segment ofWSN for the 5V
terminal 70 nt, whereas the pPR-NA35 derived vRNAs share
only the terminal 28 noncoding nt with the wt NA segment.
We examined whether the length of the 5V terminal sequence
had an effect on the efficiency with which the dicistronic
vRNA molecules were replicated and transcribed by the
influenza RNA polymerase complex upon transient reconsti-
tution of vRNPs in vivo. The pPR-NA35-CAT or pPR-NA38-
CAT plasmids were transfected into COS-1 cells together with
the four pcDNA-PB1, -PB2, -PA and -NP plasmids. Total RNA
was extracted 48 h later and analyzed by Northern blot using a
positive-sense riboprobe specific for CAT sequences. As shown
in Fig. 2A, full-length genomic vRNAs containing NA and
CAT sequences (closed arrowheads) and shorter subgenomic
vRNAs containing CAT sequences (open arrowheads) were
detected at similar levels whether cells had been transfected
with the pPR-NA35-CAT or pPR-NA38-CAT plasmid. Ge-
nomic and subgenomic cRNAs/mRNAs were synthesized at
similar levels from the pPR-NA35-CAT and pPR-NA38-CAT
constructs, as revealed when a negative-sense CAT riboprobe
was used (Fig. 2B). No subgenomic RNA molecules were
observed in cells transfected with the control pPR-NA37-CAT
plasmid, which lacked the internal 3V promoter sequence (Figs.
1, 2A and B). Similar results were obtained when the GFP or
VP0c reporter genes were used (data not shown). In agreement
with what was observed at the RNA level, similar amounts of
CAT were measured in cytosolic extracts from cells transfected
with the pPR-NA35-CAT or pPR-NA38-CAT plasmids (Fig.
2C). These results thus showed that the presence of an
extended terminal sequence derived from the wt NA segment
at the 5V end of the dicistronic NA38-CAT vRNAs did not
significantly affect the efficiency with which they underwent
both genomic and subgenomic transcription/replication by the
influenza polymerase complex expressed transiently, as com-
pared to the NA35-CAT vRNAs.
Characterization of recombinant viruses with dicistronic NA
segments of the NA35 and NA38 series
We next compared the efficiency with which recombinant
influenza viruses carrying a dicistronic segment could be
rescued from plasmids of the NA35 and NA38 series. The
various NA35 and NA38 vRNPs were reconstituted in COS-1
cells simultaneously infected with the WSN-HK helper virus,
as described by Pleschka et al. (1996). As observed in our
previous study (Vieira Machado et al., 2003), vNA35-CAT and
vNA35-VP0c viruses were recovered at low titers from the
supernatant of COS-1 cells (101 to 102 and 102 to 103 pfu/ml,
respectively), whereas the NA35-GFP dicistronic vRNAs could
not be rescued into infectious viruses. In contrast, all three
NA38-CAT, NA38-VP0c and NA38-GFP vRNAs were rescued
into infectious viruses. Remarkably, titers obtained for vNA38-
Fig. 2. Transient expression of the CAT gene from the recombinant dicistronic NA35-CAT and NA38-CAT vRNAs. Subconfluent monolayers of COS-1 cells were
transfected with plasmids pcDNA-PB1, -PB2, -PA and -NP, together with each of the indicated polI expression plasmids, as described under Materials and methods.
At 48 h post-transfection, total cellular RNA was prepared and analyzed by Northern blot for the presence of negative sense vRNAs (A) or for the presence of
positive-sense cRNAs or mRNAs (B) with positive- (A) or negative- (B) sense 32P-labeled riboprobes specific for CAT sequences, prior to exposure on a Storm
phosphorimager (Molecular Dynamics). Positions of genomic (closed arrowheads) and subgenomic (open arrowheads) RNAs and of molecular weight markers (kb)
are indicated. In parallel, cytosolic cell extracts were prepared at 24 (hatched bars) or 48 h (black bars) post-transfection and assayed for CAT levels (C). Levels are
given in nanograms of CAT protein for 106 transfected cells.
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to those obtained for recombinant viruses with a wt NA
segment (105 to 106 pfu/ml).
The recombinant viruses were plaque purified twice on
MDBK cells, and the growth properties of several independent
clones were examined. First, their plaque phenotype was
evaluated in MDCK cells under an agarose overlay in the
presence of 2% FCS. Although they were slightly smaller than
those observed with the wt vNA or the control vNA38 viruses,
plaques formed by the vNA38-CAT and vNA38-VP0c viruses
were significantly larger than those formed by their vNA35-CAT
and vNA35-VP0c counterparts (Fig. 3A). The vNA38-GFP
virus, however, gave small-sized plaques. In order to compare
more precisely the efficiency of multiplication of the vNA35-
CAT and vNA38-CAT viruses, their growth kinetics were
analyzed on MDCK cells in parallel with those of the vNA,
vNA35 and vNA38 viruses. As previously reported, the growth
rate of the vNA35-CATviruswasmarkedly reduced as compared
to the wt vNAvirus, with titers reaching the level of 107 pfu/ml as
compared to 109 pfu/ml for thewt (Fig. 3B). In agreementwith its
larger plaque phenotype, the vNA38-CAT virus grew more
efficiently than the vNA35-CAT virus. Titers observed with the
vNA38-CAT virus at 48 h post-infection (about 3 108 pfu/ml)
were intermediate between those observed with the vNA35-CAT
and wt vNAviruses and in the same range as those observed for
the vNA35 and vNA38 viruses (Fig. 3B).
The presence of the dicistronic segments was examined for
two independent clones of each of the recombinant viruses of
the vNA38 series, and their genetic stability was evaluated
upon serial passage on MDCK cells at a low m.o.i. RT-PCR
was performed on viral RNA extracted from working stocks at
passage P1, passage P2 or P3, and at the sixth (P6) passage.
Primers NA/+/1085 and NA/NC/5V located in the NA ORF and
5V NCR, respectively, allowed amplification of the whole
region of insertion within the NA segment (Fig. 3C). PCRproducts of the expected size were observed for all clones
analyzed at P1 (Fig. 3C). Direct sequencing of the PCR
products confirmed that the duplicated 3V NCR and entire
foreign sequences (CAT, VP0c or GFP) were present and
unmodified as compared to those of the plasmids from which
the viruses were derived. The 5V and 3V terminal NCRs of the
dicistronic segments were submitted to RACE analysis and
appeared to be identical to those of the wild-type vNA virus.
For all clones analyzed except for one of the vNA38-GFP
viruses, the inserted sequences were found to be stably retained
within the NA segment up to P6 (Fig. 3C). For vNA38-GFP
clone #1, PCR products of a smaller size than expected,
corresponding most likely to partial deletions of the GFP
sequence, were detectable as soon as P1 and became prominent
at P3. In agreement with the genetic instability revealed by RT-
PCR analysis, plaques formed by the vNA38-GFP clone #1
virus were heterogeneous and larger in size at P3 as compared
to P1 (data not shown). In contrast, the plaque phenotype of the
vNA38-GFP clone #2 virus, as well as that of the vNA38-CAT
and vNA38-VP0c viruses, remained stable up to P6. Notice-
ably, trace amounts of an additional DNA fragment, migrating
at the same distance as the PCR product amplified from the wt
vNA segment, were produced in all amplification reactions
(Fig. 3C). Because this fragment was also produced in control
amplifications performed on the various pPR-NA38 plasmids
and showed the same relative intensity after several passages, it
most likely represented a PCR artefact rather than a reversion
to the wild-type genotype.
CAT and NA expression in cells infected with the vNA35-CAT
or vNA38-CAT dicistronic viruses
We next compared the efficiency with which the dicistronic
NA segment from vNA35-CAT and vNA38-CAT viruses was
replicated and transcribed by the polymerase complex
Fig. 3. Plaque phenotype and in vitro multiplication and stability of recombinant viruses with dicistronic NA segments of the NA35 and NA38 series. (A) The plaque
phenotype of the indicated recombinant viruses was assayed on MDCK cells in a standard plaque assay as described under Materials and methods. Cell monolayers
were stained with crystal violet after 3 days of incubation at 35 -C and are shown for one clone representative of each type of virus. Virus vNA35-GFP could not be
rescued. (B) Growth kinetics of the recombinant viruses. Confluent MDCK cell monolayers were infected with the indicated recombinant viruses at an m.o.i. of
0.001. At the indicated time points, the supernatants were collected, and viral titers (pfu/ml) were determined on MDCK cells, using a standard plaque assay. (C)
Genetic stability of the recombinant viruses. Two independent clones (C1, C2) of the indicated recombinant viruses were passaged 6 times on MDCK cells at an
m.o.i. of 0.01. The viral RNAs from the first (P1), an intermediate (P2 or P3) and the last (P6) passages of the indicated recombinant viruses or from wt vNA virus
were analyzed by RT-PCR using the NA/+/1085 and NA/NC/5V oligonucleotide primers, as described under Materials and methods. The position of the primers is
indicated by solid arrows on a schematic drawing of the vNA38-CAT vRNA. Corresponding plasmid DNAs were amplified in parallel as positive controls. The
amplified products were analyzed on a 1% agarose gel and visualized by ethidium bromide staining. MW: molecular weight markers; the size (nt) is indicated on the
left. Ø: amplification of RNA from mock-infected cells.
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cells were infected at an m.o.i. of 2 with two independent
clones of vNA35-CAT or vNA38-CAT or with the control
vNA35 or vNA38 viruses. Total RNA was extracted at 24
h post-infection and analyzed by Northern blot. As found
earlier in the transient expression assay, genomic and sub-
genomic vRNAs were detected when a positive-sense CAT-
specific riboprobe was used (Fig. 4A). Similarly, genomic and
subgenomic cRNAs/mRNAs were detected when a negative-sense CAT-specific riboprobe was used (Fig. 4B). The levels of
genomic RNAs appeared slightly higher in cells infected with
vNA38-CAT as compared to vNA35-CAT. More strikingly, the
relative levels of genomic and subgenomic RNAs were
inverted: vNA35-CAT subgenomic RNAs were far less
represented than the corresponding genomic RNAs, whereas
vNA38-CAT subgenomic RNAs were more abundant than the
corresponding genomic RNAs (Figs. 4A and B). Similar results
were obtained on MDCK cells and when subgenomic RNAs
Fig. 4. Expression of the CAT gene by the dicistronic vNA35-CAT and vNA38-
CAT viruses. Monolayers of COS-1 cells were mock infected or infected with
the wild-type vNA or the indicated recombinant viruses at an m.o.i. of 2. Total
cellular RNAwas prepared at 24 h post-infection and analyzed by Northern blot
for the presence of genomic (closed arrowheads) and subgenomic (open
arrowheads) vRNAs (A) or for the presence of positive-sense cRNA and
mRNAs (B) with positive- (A) or negative- (B) sense 32P-labeled riboprobes
specific for CAT sequences, prior to exposure on a Storm phosphorimager
(Molecular Dynamics). The position of molecular weight markers (kb) is
indicated. (C) Cytosolic cell extracts were prepared at 8 (hatched bars) or 24
h (black bars) post-infection and assayed for CAT levels as described under
Materials and methods. Levels are given in nanograms of CAT protein for 106
infected cells.
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cells (data not shown). Next, RNA samples prepared from
infected MDCK cells were analyzed for the levels of NA-
specific vRNA and c/mRNA, using the NP gene as an internalcontrol (Figs. 5A and B). Only slight variations of the levels of
NP vRNA and cRNA were observed between dicistronic and
wt vNA virus-infected cells. In contrast, the levels of NA
vRNA and cRNA showed significant variations, depending
both on the length of the inserted sequence and on the presence
of the last 42 nt of the NA ORF next to the 5V NCR. The length
effect was most striking in cells infected with dicistronic
viruses of the NA35 series. Indeed, the amount of NA vRNA in
vNA35, vNA35-VP0c and vNA35-CAT infected cells repre-
sented 36, 17 and 3%, respectively, of the amount of vRNA
detected in wt vNA-infected cells (Fig. 5A). On the other hand,
much higher levels of NA vRNAs were found in cells infected
with the vNA38-CAT as compared to the vNA35-CAT virus
(22% of the levels associated with vNA infection, as compared
to 3%). Such an increase was also observed when the vNA38
and vNA35 viruses were compared but not when the vNA38-
VP0c and vNA35-VP0c viruses were compared (Fig. 5A).
Variations of the levels of NA cRNA followed very much the
same pattern as observed for the NA vRNA (Fig. 5B).
The production ofCATandNAproteinswas then compared in
cells infected with the vNA35-CAT or vNA38-CAT viruses.
Amounts of CATwere measured by ELISA in cytosolic extracts
prepared from COS-1 cells at 8 or 24 h post-infection and were
found to bemore than 2 logs higher in vNA38-CAT infected cells
than in vNA35-CATinfected cells. As shown in Fig. 4C, levels of
CAT produced upon infection with vNA38-CAT and vNA35-
CAT were 400 T 20 ng/106 cells and 1.1 T 0.7 ng/106 cells,
respectively, at 8 h post-infection, and they increased to 5400 T
470 ng/106 cells and 12T5ng/106 cells, respectively, at 24 h post-
infection. Similar results were obtained on MDCK cells and
when production of the VP0c polypeptide was compared in
vNA38-VP0c and vNA35-VP0c infected cells (data not shown).
Expression of NA at the cell surface was examined by FACS
analysis performed on MDCK cells at 8 h post-infection. As
shown in Fig. 5C, MDCK cells infected with the control vNA35
or vNA38 viruses expressed the same amounts of NA as
compared to cells infected with the wt vNA virus, whereas
expression of the NA was reduced in cells infected with
dicistronic viruses. However, the reduction was significantly
lower in cells infected with vNA38-CAT (34%) as compared to
vNA35-CAT (71%). A similar observation was made when
comparing MDCK cells infected with the vNA38-VP0c or
vNA35-VP0c viruses, as they expressed 28% and 55% less NA,
respectively, than cells infected with the vNAvirus (Fig. 5C).
On the whole, our results showed that expression of the NA,
CAT and VP0c proteins was higher in cells infected with the
vNA38-CAT or vNA38-VP0c as compared to the vNA35-CAT
or vNA35-VP0c viruses, respectively, which correlated with a
strong increase in the synthesis of the subgenomic RNA
species and, in some cases, with a moderate increase in the
synthesis of the genomic RNA species.
Packaging of the vNA38-CAT subgenomic RNAs into viral
particles
We asked whether the subgenomic vRNAs that appeared to
be efficiently replicated in cells infected with the vNA38-CAT
Fig. 5. Expression of the NA gene by the dicistronic viruses of the NA35 and NA38 series. Monolayers of MDCK cells were mock infected or infected with the wild-
type vNA or the indicated recombinant viruses at an m.o.i. of 2. Total cellular RNA was prepared at 24 h post-infection and analyzed by Northern blot for the
presence of genomic NA vRNAs (A) or for the presence of positive-sense cRNA and mRNAs (B) with positive- (A) or negative- (B) sense 32P-labeled riboprobes
specific for NA sequences, prior to exposure on a Storm phosphorimager (Molecular Dynamics). The position of molecular weight markers (kb) is indicated on the
side. As a control, Northern blot analysis was performed in parallel using positive- (A) or negative- (B) sense 32P-labeled riboprobes specific for NP sequences. The
amounts of NA and NP-specific RNAs were quantified, and the calculated NA/NP-specific RNAs ratios are indicated (1 = the ratio found in vNA-infected cells). (C)
At 8 h post-infection, the cells were detached and labeled with the anti-NA mouse monoclonal antibody 10C9. Bound antibodies were detected with FITC-
conjugated anti-mouse IgG antibodies and, after fixation of the cells in PBS-PFA, flow cytometry analysis was performed on a FACScalibur fluorocytometer
(Becton-Dickinson).
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with the 8 genomic segments. MDCK cells were infected with
the vNA38-CAT virus at an m.o.i. of 0.01. The supernatant was
collected 72 h later, clarified and fractionated on a sucrose
gradient as described under Materials and methods. RNA was
extracted from each fraction and analyzed by Northern blot
using a positive-sense CAT riboprobe. As shown in Fig. 6A, the
peak of detection of an RNA species corresponding in size to the
full-length NA38-CAT genomic vRNA (closed arrowhead)
coincided with fractions 7 to 10, the highest amounts being
detected in fraction 9. The presence of a smaller RNA species
corresponding in size to the subgenomic CAT vRNA (open
arrowhead) was also detected in fractions 7 to 10, the relative
amount of the large and small RNA species being conserved
from one fraction to another. In parallel, the infectious titer of
each fraction of the gradient was determined by plaque assay,and a co-sedimentation of infectious particles with genomic and
subgenomic RNAs was clearly observed (Fig. 6B). In order to
confirm that the subgenomic vNA38-CATRNAswere packaged
into viral particles, fraction 9 was submitted to dialysis and
divided into aliquots that were either treated with S7 nuclease,
with Triton X100, with S7 nuclease and Triton X100 simulta-
neously or mock-treated. RNA was extracted from the treated
samples, as well as from an aliquot of fraction 9 left untreated,
and analyzed by Northern blot as described above. The result is
shown in Fig. 6C. The amounts of genomic and subgenomic
RNAs were identical in the untreated and mock-treated samples
and in the samples that had been treated with the S7 nuclease or
Triton X100 alone. Only if performed in combination with the
Triton X100 extraction did the S7 nuclease digestion result in
complete disappearance of the genomic and subgenomic RNAs.
The most straightforward interpretation of this result is that
Fig. 6. Packaging of subgenomic vRNAs into vNA38-CAT viral particles. Confluent monolayers of MDCK cells were infected with vNA38-CAT virus at an m.o.i.
of 0.01. At 72 h post-infection, the cell supernatant was collected, loaded onto a 15–40% (w/v) sucrose gradient, centrifuged and fractionated as described under
Materials and methods. (A) RNAwas extracted from the indicated fractions or from an aliquot of the cell supernatant (INPUT) and analyzed by Northern blot for the
presence of genomic (closed arrowheads) and subgenomic (open arrowheads) vRNAs with a positive-sense 32P-labeled riboprobe specific for CAT sequences, prior
to exposure on a Storm phosphorimager (Molecular Dynamics). (B) Viral titers (pfu/ml) in the indicated fractions were determined on MDCK cells, using a standard
plaque assay. (C) Fraction 9 was submitted to dialysis, and aliquots were subsequently treated with Triton X100, with S7 nuclease, or with both simultaneously, as
described under Materials and methods. Control aliquots were mock treated or left untreated. RNAwas extracted from the various aliquots and analyzed by Northern
blot for the presence of genomic (closed arrowheads) and subgenomic (open arrowheads) vRNAs, as described above.
A. Vieira Machado et al. / Virology 345 (2006) 73–8780solubilization of the viral envelope with Triton X100 was
required for RNAs to become accessible to the nuclease. Thus,
our data strongly suggest that both the genomic and subgenomic
vNA38-CAT RNAs were packaged into viral particles.
Viral replication and expression of an heterologous protein in
mice inoculated with dicistronic viruses of the vNA38 series.
Comparison of vNA35-CAT and vNA38-CAT
In order to compare the potential of dicistronic viruses of the
NA35 and NA38 series to replicate in the respiratory tract of
mice, male C57BL/6 mice were inoculated intranasally with 103
pfu of wt vNA virus, dicistronic vNA35-CAT or vNA38-CAT
virus. An independent experiment with a similar design was
performed to test the vNA38-VP0c virus, in parallel with the
vNA and vNA38 viruses.
According to previous experiments, 103 pfu of the vNAvirus
which corresponded to 0.1 LD50 induced a nonlethal viral
pneumonia in more than 95% of the infected mice (Vieira
Machado et al., 2003). Indeed, in mice inoculated with the vNA
virus, as well as in mice inoculated with the vNA38, vNA38-
CAT or vNA38-VP0c virus, and to a lower extent in mice
inoculated with the vNA35-CAT virus, the lungs harvested at 4
days post-inoculation (p.i.) showed macroscopic lesions typical
of viral pneumonia. At 7 days p.i., the lungs of vNA and vNA38-
CAT infected mice showed a broad hepatized aspect, whereasthe lung lesions of vNA35-CAT infected mice remained
scattered (data not shown). At 4 days p.i., pulmonary viral loads
in mice infected with vNA38-CAT were slightly reduced as
compared to vNA-infected mice (5.5 T 0.3 versus 6.1 T 0.1 log10
pfu/lungs, P  0.01, Fig. 7A). Similarly, viral loads found in
mice infected with vNA38-VP0c were slightly lower at 4 days
p.i. (a less than 0.5 log10 reduction was observed, P < 0.02, Fig.
7B). At 7 days p.i., viral loads inmice infected with vNA38-CAT
remained high and were not significantly different from those
measured in mice infected with the vNA virus (5.7 T 0.4 versus
6.1 T 0.3 log10 pfu/lungs, P = 0.1, Fig. 7A). In contrast,
pulmonary viral loads in mice infected with vNA35-CAT kept
decreasing from day 4 (4.1 T 0.7 log10 pfu/lungs) to day 7 p.i.
(3.3 T 0.4 log10 pfu/lungs), underlining the attenuated phenotype
of this virus in mice. On the whole, these results suggested that
dicistronic viruses of the vNA38 series could replicate in the
lower respiratory tract of mice more efficiently than vNA35
viruses and almost as efficiently as the wt virus, which was in
agreement with the growth curves observed in cell culture.
The genome of the viruses recovered from the lung homo-
genates was analyzed by RT-PCR, using primers NA/+/1085 and
NA/NC/5V as mentioned above. As indicated by the size of the
PCR products, both vNA-38-CAT (Fig. 7C) and vNA-38-VP0c
(Fig. 7D) retained the foreign inserted sequences upon multipli-
cation in the respiratory tract ofmice, thus showing that dicistronic
viruses of the vNA38 series were genetically stable in vivo.
Fig. 7. Multiplication of recombinant viruses with NA38 dicistronic segments in mice and expression of an heterologous protein in vivo. Groups of six (A) or five
(B) C57BL/6 mice were infected intranasally with 103 pfu of the indicated viruses. Four or seven days after inoculation, mice were euthanized, and lung
homogenates were prepared and titrated for infectious virus by plaque assay on MDCK cells. Viral titers were expressed as log10 (pfu/lungs) for individual mice. The
titration limit is indicated by the dotted line. (C, D) Viral RNAs from the inoculated viruses (inoc.) or from viruses recovered from the lungs of individual mice (#1–
6) were extracted and analyzed by RT-PCR using the NA/+/1085 and NA/NC/5V oligonucleotide primers, as in Fig. 3. The amplified products were analyzed on a 1%
agarose gel and visualized by ethidium bromide staining. M: molecular weight markers; the size (kb) is indicated on the side. Mock: amplification of RNA from
mock-infected mice. (E) C57BL/6 mice were infected intranasally with 105 pfu of vNA, vNA35-CAT or vNA38-CAT viruses as indicated. Four days later, lung
homogenates from individual mice were assayed for CAT expression. Levels are expressed in nanograms of CAT protein per lungs. The detection limit (0.19 ng of
CAT/lungs) is indicated by the dotted line.
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expression of an heterologous protein in vivo. Mice were
inoculated with 105 pfu of either the vNA35-CAT or vNA38-
CAT virus, and CAT levels were measured by ELISA in lung
homogenates prepared at 4 days post-inoculation. As shown in
Fig. 7E, CAT could not be detected in the lungs of mice
inoculated with vNA35-CAT (0.19 ng/lungs), whereas a
significant expression of CAT (21.6 T 4.2 ng/lungs) was
observed in the lungs of mice inoculated with vNA38-CAT.
These observations suggest that during their multiplication inmice, dicistronic viruses of the vNA38 series allow subgenomic
vRNAs to be replicated and transcribed and an heterologous
protein to be synthesized in the infected pulmonary tissues.
Induction of humoral and cellular immune responses in mice
inoculated with dicistronic viruses of the vNA38 series.
Comparison of vNA35-CAT and vNA38-CAT immunogenicity
We examined further whether an immune response against
the heterologous CAT or VP0c protein could be generated in
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virus. C57BL/6 mice were inoculated intranasally with 103 pfu
of vNA35-CAT, vNA38-CAT, or vNA38-VP0c, or control
vNA or vNA38 virus. Sera were sampled at 3 weeks post-
inoculation and tested for the presence of anti-influenza
antibodies by ELISA. High antibody titers were found in mice
inoculated with the wt virus and in mice inoculated with the
dicistronic vNA38 viruses as well, indicating that expression of
an heterologous protein by the vNA38-CAT and vNA38-VP0c
viruses did not modify their influenza-specific immunogenicity
(Figs. 8A and C). In accordance with their reduced replication
rate in vivo, significantly lower antibody titers were found in
mice inoculated with the vNA35-CAT virus (5.2 T 0.2 versus
5.8 T 0.2 log10 titer, P < 0.01).
Sera harvested from mice inoculated with the vNA, vNA35-
CAT or vNA38-CAT viruses were also tested for the presence
of anti-CAT antibodies. As shown in Fig. 8B, moderate but
significant titers of anti-CAT antibodies were measured in 6 out
of 8 mice inoculated with vNA38-CAT, whereas a single out of
7 vNA35-CAT-inoculated mice showed only low levels of anti-
CAT antibodies.
Induction of an heterospecific cellular response was
examined in mice that had been inoculated with the vNA38-
VP0c or vNA38 viruses. Spleen cells harvested at 2 months
post-inoculation were tested by ELISPOT for the presence of
Mengo virus-specific CD8+ T lymphocytes, using the Mengo-Fig. 8. Anti-influenza and anti-CAT antibody response and Mengovirus-specific CD
mice were inoculated intranasally under light ketamine anesthesia with 103 pfu of th
Antibody titers are represented as the reciprocal of the highest dilution of each serum
an ELISA test using purified split influenza A/PR/8/34 (A, C) or purified CAT prot
Splenocytes from mice infected with vNA38 or vNA38-VP0c viruses were harvested
IFNg-producing T cells by ELISPOT using the immunodominant VP2121 – 130 peptvirus VP2121–130 immunodominant H-2D
b peptide (Dethlefs et
al., 1997). IFNg-producing T cells were detected in response to
the VP2121–130 peptide when splenocytes were isolated from
all six vNA38-VP0c inoculated mice but not from four control
vNA38 inoculated mice (Fig. 8D). Mengovirus-specific T cell
precursor frequencies ranging between 8 and 23 per 106
splenocytes (average 17 T 6) were observed in vNA38-VP0c
infected mice, as compared to less than 1 per 106 splenocytes in
control mice (average 0.8 T 0.4), demonstrating that a modest
but significant heterospecific CD8+ T cell response was
induced upon infection with the vNA38-VP0c virus.
Discussion
Based on observations from Flick and Hobom (1999), we
showed previously that it was possible to have a foreign gene
expressed by stable recombinant influenza viruses harboring a
dicistronic NA segment with an internal duplicated 3V promoter
(vNA35 viruses) (Vieira Machado et al., 2003). Here, we
describe a second generation of dicistronic influenza viruses
with improved characteristics as vectors for the delivery of
heterologous proteins, called vNA38 viruses. The dicistronic
NA segments from the vNA38 as well as vNA35 viruses
contain the NA ORF downstream of the original 3V promoter
and a second ORF (CAT, GFP or VP0c) downstream of the
duplicated 3V promoter. The two types of viruses differ only in8+ T cells response in mice infected with dicistronic vNA38 viruses. C57BL/6
e indicated recombinant viruses. Sera were collected 3 weeks after inoculation.
sample giving an optical density equal to five times that of background levels in
ein (B) as antigen. The limits of detection are indicated by the dotted line. (D)
2 months after inoculation and assayed for the presence of Mengovirus-specific
ide, as described under Materials and methods.
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NA segment of WSN at the 5V end, i.e., 70 nt for the vNA38
viruses, instead of the 28 noncoding nt only for the vNA35
viruses. The recombinant vNA38-CAT and -VP0c viruses
showed an improved capacity of multiplication in vitro as
compared to their vNA35-CAT and -VP0c counterparts. This
improvement could be correlated with higher steady-state
levels of NA vRNA, c/mRNAs and protein, in cells infected
with the vNA38-CAT and -VP0c viruses as compared to the
vNA35-CAT and -VP0c viruses, respectively. Recombinant
vNA38-GFP viruses could be rescued, whereas attempts to
rescue vNA35-GFP viruses remained unsuccessful. However,
vNA38-GFP viruses grew to lower titers and formed smaller
plaques as compared to the vNA38-CAT and -VP0c viruses.
This reduced growth capacity could be due to the larger size
(720 nt, as compared to 660 and 306 nt for CAT and VP0c,
respectively) or to the nature, such as the higher GC content
(62%, as compared to 45 and 48% for CAT and VP0c,
respectively), of the GFP insert, as previously discussed (Vieira
Machado et al., 2003). Indeed, the GC content of the WSN
genome segment is 43.9 T 1.5% and sequences with a
significantly higher GC content may not be efficiently
replicated by the viral polymerase. Such differences in GC
content could also account for the findings by Lu et al. and
Kittel et al. that recombinant influenza viruses carrying the
GFP sequences within the NS segment are unstable upon
multiple passages in cell culture (Kittel et al., 2004; Lu et al.,
2004). Except for one vNA38-GFP clone, all the recombinant
dicistronic viruses of the vNA38 series were found to be stable,
as they did not show mutations in noncoding sequences of the
NA segment and retained the inserted sequences upon serial
passages in cell culture. However, mutations in the NA ORF
(resulting in an increased activity of the NA) or the HA ORF
(resulting in a decreased dependence on NA activity) may have
been selected if they could compensate for the slightly reduced
synthesis of NA by the recombinant vNA38 viruses as
compared to the wt (Gubareva et al., 1996).
Production of the foreign CAT polypeptide was more than 2
logs higher in cells infected with the vNA38-CAT virus than in
cells infected with its vNA35 counterpart. The levels of CAT
subgenomic vRNAs and c/mRNAs were also dramatically
increased in cells infected with vNA38-CAT as compared to
vNA35-CAT, whereas the levels of NA-CAT genomic vRNAs
and c/mRNAs were only slightly higher. Similar observations
were made when production of the VP0c polypeptide was
compared in vNA38-VP0c and vNA35-VP0c infected cells. In
contrast, no GFP expression and no subgenomic RNAs could
be detected in cells infected with the vNA38-GFP virus (data
not shown). GFP expression could be detected, however, upon
transient reconstitution of vRNPs in COS-1 cells with either the
NA38-GFP segment or a 38-GFP minigenome corresponding
to its subgenomic vRNA (data not shown). This observation
further suggested that in the context of viral infection, the
NA38-GFP vRNA sequence may not efficiently compete with
wild-type segment for replication by the viral polymerase. On
the whole, our results indicate that the level of expression of
the transgene located downstream the internal duplicated 3Vpromoter is correlated to the level of synthesis of the
subgenomic RNAs. Although size and/or sequence limitations
might occur, as suggested by the absence of GFP protein
expression in vNA38-GFP infected cells, vNA38 viruses
appear as improved vectors for gene delivery as compared to
vNA35 viruses. They offer a large coding capacity and the
possibility to express native proteins devoid of additional
sequences, as do vNA35 viruses and as discussed previously
(Vieira Machado et al., 2003), but they allow much higher
levels of expression of the transgene to be achieved.
How could improved growth properties and increased
expression of the transgene relate to the fact that the dicistronic
segment harbored 5V end sequences identical to that of the wt
NA over 70 nt for vNA38 viruses, instead of 28 nt for vNA35
viruses? We found that this difference in the length of the 5V
terminal sequence had no effect on the efficiency with which
genomic and subgenomic RNA molecules were replicated and
transcribed by the influenza RNA polymerase complex upon
transient reconstitution of vRNPs in COS-1 cells. We cannot
rule out that this transient assay might fail to reveal putative
transcription/replication defects of the NA35 constructs, due to
the lack of competition of the dicistronic NA segments with
wild-type segments. However, given the finding by Fujii et al.
that both ends of the NA coding region are required for
incorporation of the NA segment into virions (Fujii et al.,
2003), the most likely interpretation of our data is that the
presence of an extended 70 nt long 5V end sequence including
the last 42 nt of the NA ORF in addition to the 28 nt of the
5VNC region in the vNA38 dicistronic segments promotes
efficient packaging of these segments into viral particles and
thus efficient propagation of the vNA38 recombinant dicis-
tronic viruses. Indeed, using an influenza minigenomes/helper
virus system, we could demonstrate that the NA ORF last 42 nt
specifically and efficiently promote packaging of genomic
vRNA-like molecules (Leclercq et al., manuscript to be
submitted). Moreover, our analysis of the RNAs extracted
from sucrose gradient-purified virions strongly suggested that
not only the genomic but also the subgenomic vNA38-CAT
vRNAs were efficiently packaged into viral particles. This
finding probably accounts for the differences observed in the
relative levels of genomic versus subgenomic RNAs between
cells infected with vNA38- and vNA35-CAT viruses. Our
hypothesis is that little or no subgenomic vRNAs are delivered
by infectious vNA35-CAT particles. According to this hypoth-
esis, the subgenomic vRNAs detected in vNA35-CAT infected
cells are mainly generated by internal initiation events
involving interaction of the 5V promoter with the internal 3V
promoter sequence and subsequent amplification by the viral
polymerase. Similarly, subgenomic mRNAs may either be
generated from internal initiation reactions during transcription
of genomic vRNAs or result from the transcription of
subgenomic vRNAs. The ratio of subgenomic to genomic
RNAs in vNA35-CAT infected cells was low, suggesting that
internal initiation by the polymerase complex was unfrequent
in the course of viral infection. In contrast, in vNA38-CAT
infected cells, subgenomic RNAs were much more abundant
than genomic RNAs, which probably resulted from two factors.
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CAT infectious particles and could thus be present in the
nucleus of infected cells independently of the occurrence of
internal initiation reactions. Second, subgenomic RNAs likely
underwent preferential amplification by the polymerase com-
plex due to their small size, as compared to the genomic RNAs.
The question remains whether subgenomic RNAs are packaged
into viral particles as a ninth segment (as already shown to
occur, Enami et al., 1991) or whether they compete specifically
for packaging with the genomic dicistronic RNAs (as
suggested by previous observations on defective viral RNAs,
Duhaut and Dimmock, 2002; Odagiri and Tashiro, 1997).
The vNA38-CAT and vNA38-VP0c viruses proved to
replicate efficiently and to be stable not only in MDCK cell
culture but also in vivo in the pulmonary tissue of infected
mice. In vNA38-CAT inoculated mice, moderate levels of CAT
protein and anti-CAT antibodies were measured in the lungs
and serum, respectively. In agreement with its reduced growth
and expression capacity in vitro, vNA35-CAT had an
attenuated phenotype and was far less immunogenic in mice.
In vNA38-VP0c inoculated mice, a modest but significant
Mengo virus-specific CD8+ T cell response was detected. In
these experiments, the intensity of the immune responses might
have been limited by the low level of expression of the
heterologous protein in the lung of mice and/or by the low
antigenicity of these antigens. Using well-characterized anti-
gens, such as the HBS surface antigen of hepatitis B virus or
the nucleoprotein of LCMV virus, could help in evaluating the
induction of a protective immune response of humoral or
cellular nature, respectively, by vNA38 dicistronic viruses.
These studies are currently in progress. If applied to attenuated
influenza viruses (such as the cold-adapted strain which has
recently been used as a live-attenuated influenza vaccine,
Belshe et al., 2004), the dicistronic approach could potentially
be used as a new strategy for vaccination against respiratory or
other pathogens for humans. To this end, it could also be of
interest to engineer dicistronic vRNA molecules from another
segment than the NA (or HA) segment. This would alleviate
the need for engineering dicistronic NA segments from each
new vaccine strain and would allow the use of various
influenza virus subtypes for efficient prime-boost immuniza-
tions (Ferko et al., 2001) or in order to circumvent any
preexisting immunity to the vector. The NS segment would be
a good candidate because (a) a greater coding capacity can be
expected from its smaller size; (b) the packaging signals
specific for the NS segment have been recently described (Fujii
et al., 2005); (c) deletion of the sequences encoding NS1 has
been shown to confer an attenuated phenotype (Egorov et al.,
1998; Garcia Sastre et al., 1998) and would also help avoid
interference between the alternative splicing of the mRNA
required for the expression of the NEP protein and the
transcription of subgenomic RNAs required for expression of
the foreign protein. Such a dicistronic attenuated influenza
virus could represent an alternative expression vector, in
addition to the neuraminidase-deficient influenza A viruses
recently described by Shinya et al. and Mishin et al., that have a
great coding capacity but allow expression of foreign proteinsas fusion polypeptides with the 61 or 56 N-terminal residues of
the NA, respectively (Mishin et al., 2005; Shinya et al., 2004).
Which vector would successfully achieve the optimal balance
between attenuation, safety and immunogenicity will have to
be determined experimentally in suitable models.
Materials and methods
Cells and viruses
MDBK and MDCK cells were grown at 37 -C under 5%
CO2 in complete Dulbecco’s modified Eagle medium
(DMEM), supplemented with 5% heat-inactivated fetal calf
serum (FCS). COS-1 cells were grown in DMEM supplemen-
ted with 10% FCS.
Influenza virus A/WSN/33 (WSN, H1N1) and the WSN/HK
(H1N2) reassortant were kindly provided by Dr. Peter Palese
(Mount Sinaı¨ School of Medicine, New York, USA). Viral
stocks were produced by serial allantoic passage on 11-day-old
embryonated hen’s eggs.
Plasmids
For reverse genetics, cDNAs corresponding to the wild-type
or recombinant NA segments of the WSN influenza virus were
cloned in negative-sense polarity into plasmid pPR7 (Cres-
cenzo-Chaigne et al., 1999), under the control of the human
RNA polymerase I promoter and the hepatitis y ribozyme.
Plasmids pPR-NA, as well as plasmids of the pPR-NA35 and
pPR-NA37 series, have been described in detail earlier (Vieira
Machado et al., 2003).
To generate plasmid pPR-NA38, the 5V end of theNA segment
was amplified using plasmid pPR-NA as a template, and
oligonucleotides 5V-GACGCTAGCTGGCCAGACGGTGCT-
GAGTTGCCGTTC-3V and 5V-GTGAGCGGATAACAATTT-
CACAC-3V. The PCR product was cloned between the NheI
and HindIII sites in plasmid pPR-NA35. As a result, pPR-
NA38 contains a cDNA corresponding to a recombinant NA
segment, where the NA ORF is followed by a duplicated 3V
NCR, an XhoI-NheI multiple cloning site, a duplication of the
last 42 nucleotides of the NA ORF, and the 5V NCR (Fig. 1).
Plasmids pPR-NA38-CAT, pPR-NA38-GFP and pPR-NA38-
VP0c were obtained by subcloning the sequences encoding
the CAT protein, GFP protein and VP0c fragment
corresponding to 157–249 aa of the Mengovirus VP0c
polypeptide, respectively, between the XhoI and NheI sites
of plasmid pPR-NA38, as described earlier for plasmids of the
pPR-NA35 series (Vieira Machado et al., 2003). All constructs
were verified by the sequencing of positive clones using a Big
Dye terminator sequencing kit and an ABI377 automated
sequencer (Perkin-Elmer).
Production of recombinant viruses by reverse genetics
Production of recombinant viruses by reverse genetics was
performed by transfecting each of the pPR-NA, pPR-NA35 or
pPR-NA38 plasmids into COS-1 cells, together with expres-
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superinfecting the transfected cells with the WSN/HK helper
virus, as described previously (Vieira Machado et al., 2003).
The recovered viruses were amplified once on MDCK cells and
then plaque purified twice on MDBK cells before final
amplification on MDBK cells (viral stock P1). Subsequent
passages (P2, P3) of the recombinant viruses were performed at
an m.o.i. of 0.01 on MDCK cells for 3 days at 35 -C in DMEM
supplemented with 2% FCS. All viral stocks were titrated on
MDCK cell monolayers, in a standard plaque assay using an
agarose overlay in DMEM with 2% FCS.
Analysis of CAT expression in transfected or infected cells
For the transient expression assay, COS-1 cells were co-
transfected with plasmids pPR-NA35-CAT, pPR-NA37-CAT or
pPR-NA38-CAT, together with plasmids providing expression
of the PB1, PB2, PA and NP proteins, as described earlier
(Vieira Machado et al., 2003). Alternatively, confluent mono-
layers of MDCK cells were infected with the wt vNA or
recombinant vNA35 and vNA38 influenza viruses at an m.o.i.
of 2. Cell extracts were prepared in 500 Al of lysis buffer, either
at 24 and 48 h post-transfection or at 8 and 24 h post-infection,
and were tested for CAT levels using the CAT ELISA kit
(Roche). The lower limit of CAT detection was 0.05 ng/ml.
Analysis of NA expression in infected cells
MDCK cells grown in 35-mm dishes were infected with the
wt or recombinant WSN viruses at an m.o.i. of 2. Surface
expression of the NA was analyzed at 8 h post-infection by an
indirect immunofluorescence assay, using the mouse monoclo-
nal antibody 10C9 which is specific for the WSN-NA protein
(kindly provided by Dr. Peter Palese) and a FACScalibur
fluorocytometer (Becton-Dickinson), as described earlier
(Vieira Machado et al., 2003).
Viral RNA extraction, RT-PCR, sequencing and RACE analysis
Viral RNA was extracted with Trizol-LS reagent (Invitro-
gen) from 250 Al of cell-free supernatant according to the
manufacturer’s recommendations. The RNA was resuspended
in 20 Al of RNAse-free water, and 5 Al was used for reverse
transcription and PCR amplification using primers NA/+/1085
(spanning NA cDNA nucleotides 1085–1108) and NA/NC/5V
(complementary to nucleotides 1385–1409) as previously
described (Vieira Machado et al., 2003). A fraction of the
RT-PCR products was analyzed on a 1% agarose gel and
visualized by ethidium bromide staining. The remaining was
purified using a QIAquick PCR purification kit (Qiagen), and
the nucleotide sequence was determined using internal oligo-
nucleotides, a Big Dye terminator sequencing kit and an
ABI377 automatic sequencer (Applied Biosystems).
Sequencing of the 5V termini of the NA genomic RNA
segment was performed using an oligonucleotide/cDNA
ligation strategy. Briefly, viral RNA was submitted to reverse
transcription using as primers oligonucleotides of positivepolarity specific of the CAT, VP0c, GFP or NA coding
sequences. The resulting cDNAs were ligated to a phosphor-
ylated oligonucleotide tag with an amino group on the 3V
terminus using the T4 RNA ligase, and a fraction of the ligation
reaction was used as a template for a nested PCR amplification
as described previously (Vieira Machado et al., 2003). For
sequencing of the 3V termini, viral RNA was poly-adenylated
using the yeast poly(A) polymerase. Complementary DNAs
were prepared by reverse transcription of the poly-adenylated
RNAs using an anchored oligo-dT primer, and PCR amplifi-
cation was carried out, as described earlier (Vieira Machado et
al., 2003). The amplified products corresponding to the 5V and
3V termini of the NA segment were sequenced with internal
oligonucleotides, as described above.
Northern blot analysis
COS-1 cells grown in 35-mm dishes were transfected as
described above. MDCK cells were infected with recombinant
or wild-type vNAviruses at an m.o.i. of 2. At 24 h post-infection
or 48 h post-transfection, total cellular RNAs were isolated by
Trizol extraction (Invitrogen) according to the manufacturer’s
recommendations. When RNA was prepared from transfected
cells, RNA extraction was followed by digestion with 20 units of
DNase I (Ambion) in 60 Al of 10 mM Tris–HCl pH7.5, 2.5 mM
MgCl2, 0.1 mMCaCl2 for 60min at 37 -C, phenol extraction and
isopropanol precipitation.
After denaturation at 70 -C in 50% formamide, 2.2 M
formaldehyde, 1 running buffer (40 mM MOPS, 10 mM
sodium acetate, 2 mM EDTA, pH 7.0), samples (2 Ag) were run
on a 1.2% agarose–0.6M formaldehyde gel, blotted onto a nylon
membrane (Hybond N, Amersham) and hybridized with a NA-,
GFP-, VP0c- or CAT-specific 32P-labeled riboprobe allowing the
detection of RNAs of either negative (vRNAs) or positive
(cRNAs, mRNAs) polarity. Hybridizations and membrane
washeswere performed as previously described (VieiraMachado
et al., 2003). Finally,membranes were exposed on a STORM820
phosphorimager (Molecular Dynamics) and analyzed using the
Image Quant program (Molecular Dynamics).
Analysis of the packaging of subgenomic RNAs into viral
particles
Confluent monolayers of MDCK cells were infected with the
vNA38-CAT virus at an m.o.i. of 0.01. The cell supernatant was
collected 24 h later and clarified by two successive centrifuga-
tions at 3000 g. A fraction of the cell-free supernatant (2.5 ml)
was then loaded onto a 10 ml 15–40% sucrose (w/v) gradient in
TNE buffer (0.01 M Tris–HCl, pH 7.4; 0.15 M NaCl; 0.1 mM
EDTA) and centrifuged for 50 min at 25,000 rpm in a TST 41.14
rotor. Subsequently, 16 fractions were collected from the bottom
of the gradient. The viral titers of each fractionwere evaluated by
a standard plaque assay as described above. In parallel, RNAwas
extracted from each fraction and analyzed by Northern blot in
order to detect the presence of genomic and subgenomic vRNAs,
as described above. The fraction characterized by both the
highest vRNA content and the highest infectious titer was
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NaCl). After CaCl2 was added to a final concentration of 1mM,
80 Al aliquots of the dialyzed fraction was treated for 30 min at
20 -C either with Triton X100 0.05%, or with S7 nuclease 2 AM
(Amersham), or with both simultaneously. After the treatment
was stopped by addition of 3 mM EGTA, RNAs were extracted
and analyzed by Northern blot as described above.
Infection of mice
Male C57BL/6 mice (Charles River France) 7 to 8 weeks of
age were anesthetized lightly with 100 mg/kg of ketamine
(Merial) and inoculated intranasally with 103 or 105 pfu of
wild-type or recombinant virus in 40 Al of PBS. At 4 days post-
infection, mice were sacrificed, and lung homogenates were
prepared in PBS (3 ml) and titrated for virus on MDCK cell
monolayers, in a standard plaque assay. Statistical analyses
were performed on the log10 of the viral titers measured for
individual mice using the Student’s independent t test, with the
assumptions used for small samples (normal distribution of the
variable, same variance for the populations to be compared).
Viral RNA was extracted with Trizol-LS reagent (Invitrogen)
from 250 Al of lung homogenates and analyzed by RT-PCR, as
described above. Alternatively, viral RNA was extracted using
the QIAamp Viral RNA Mini kit (Qiagen) from 140 Al of lung
homogenates, eluted in 50 Al of RNAse-free water and
analyzed by RT-PCR using the Titan One Tube RT-PCR
System (Roche) and the NA/+/1085 and NA/NC/5V primers.
The concentration of CAT protein in lung homogenates was
determined by ELISA. Briefly, 300 Al of lung homogenates
was centrifuged for 5 min at 15,000 g at 4 -C. Supernatants
were collected, mixed with equal volumes of lysis buffer and
tested for CAT levels using the CAT ELISA kit (Roche). The
lower limit of CAT detection was 0.15 ng/lung.
Determination of antibody titers by ELISA
Blood from mice was collected 3 weeks after virus
inoculation. Serial dilutions of serum samples were tested to
determine influenza virus-specific and CAT-specific antibody
titers by indirect ELISA, using 0.5 Ag of detergent-disrupted
purified A/PR/8/34 virus or 0.25 Ag of purified CAT protein
(Sigma) per well, respectively, as antigen. Briefly, 96-well
ELISA plates (NUNC Maxisorp) were coated with the antigen
in 0.2 M Na-carbonate, pH 9.6. Following incubation with the
serum samples diluted in PBS–BSA 1%–Tween 20 0.1%,
bound antibodies were detected by successive incubations with
peroxidase-linked sheep anti-mouse IgG antibodies (Amer-
sham) and TMB peroxidase substrate (KPL). Antibody titers
were calculated as the reciprocal of the serum dilution leading
to an optical density value at 450 nm equal to five times the
background levels.
ELISPOT assay
Spleen cells were collected 3 weeks after virus inoculation
and analyzed for the presence of Mengo virus specific CD8+ Tcells in a standard ELISPOT assay. Briefly, 96-wells Multi-
screen HA nitrocellulose plates (Millipore) were coated with 4
Ag/ml rat anti-mouse IFN-g antibodies (R4-6A2, Becton-
Dickinson) in 0.2 M Na-carbonate pH 9.6. Plates were washed
and blocked with complete RPMI medium (RPMI 1650
supplemented with 10% FCS, 5  105 M 2-ß-mercaptoetha-
nol, penicillin 100 U/ml and streptomycin 100 Ag/ml) for 1 h.
106 spleen cells from infected mice were then added into the
wells along with 5  105 irradiated (2000 rad) syngeneic
spleen cells as feeder cells, 1 AM VP2121–130 synthetic peptide
(FHAGSLLVFM, Neosystem) and IL2 (10 U/ml). The cells
were incubated for 20 h at 37 -C, and after extensive washes,
the spots were revealed by successive incubations with
biotinylated rat anti-mouse IFN-g antibodies (XMG1.2, Bec-
ton-Dickinson), alkaline phosphatase-conjugated streptavidin
(Becton-Dickinson) and 5-bromo-4-chloro-3-indolylphosphate/
nitroblue tetrazolium (BCIP/NBT, Sigma) as the substrate. For
each mouse, the number of peptide-specific IFNg-producing
cells was determined by calculating the difference between the
number of spots generated in the absence and in the presence of
the VP2121–130 peptide. Results are expressed as the number of
spot-forming cells (sfcs) per 106 splenocytes.
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